Globus Medical Lowers 2026 Revenue Guidance Amid Nevro Integration Impacts
Globus Medical (GMED) reported third-quarter revenue of $763.7 million, representing a slight decline of 0.7% on an as-reported basis and 0.5% on a constant currency basis. The company attributed this softening to the ongoing rightsizing efforts related to its Nevro integration and delays in new product launches. Despite the revenue dip, management reiterated its non-GAAP earnings per share (EPS) guidance for 2026 in the range of $4.95 to $5.05. The company has adjusted its full-year 2026 revenue outlook downward to $3.09 billion as it navigates these operational transitions.